Everything below concerns reversed-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
==== Other actions ==== Phenylpiracetam binds to α4β2 nicotinic acetylcholine receptors in the mouse brain cortex with an IC50Tooltip half-maximal inhibitory concentration of 5.86 μM. Racetams generally, but including phenylpiracetam, have been described as AMPA receptor potentiators.
=== Active fascial contractility === Schleip, R.; Klingler, W.; Lehmann-Horn, F. (2005). "Active fascial contractility: Fascia may be able to contract in a smooth muscle-like manner and thereby influence musculoskeletal dynamics". Medical Hypotheses. 65 (2): 273–277. doi:10.1016/j.mehy.2005.03.005. PMID 15922099. Schleip, R.; Naylor, I.L.; Ursu, D.; Melzer, W.; Zorn, A.; Wilke, H.J.; Lehmann-Horn, F.; Klingler, W. (2006). "Passive muscle stiffness may be influenced by active contractility of intramuscular connective tissue". Medical Hypotheses. 66 (1): 66–71. doi:10.1016/j.mehy.2005.08.025. PMID 16209907. Schleip, R.; Klingler, W. (2019). "Active contractile properties of fascia". Clinical Anatomy. 32 (7): 891–895. doi:10.1002/ca.23391. PMID 31012158. Schleip, R.; Gabbiani, G.; Wilke, J.; Naylor, I.; Hinz, B.; Zorn, A.; Jäger, H.; Schreiner, S.; Klingler, W. (2019). "Fascia Is Able to Actively Contract and May Thereby Influence Musculoskeletal Dynamics: A Histochemical and Mechanographic Investigation". Frontiers in Physiology. 10 336. doi:10.3389/fphys.2019.00336. PMC 6455047. PMID 31001134.
Stimulants improve focus and alertness. Low (therapeutic) doses of dopaminergic stimulants (e.g., reuptake inhibitors and releasing agents) also promote mental and athletic performance, as cognitive enhancers and ergogenic aids respectively, by improving muscle strength and endurance while decreasing reaction time and fatigue. Stimulants are commonly used in lengthy exercises that require short bursts (e.g., tennis, team sports, etc.). Stimulants work by increasing catecholamine levels and agonistic activity at the adrenergic receptors. Examples of stimulants include caffeine, ephedrine, methylphenidate and amphetamine. Potential side effects include hypertension, insomnia, headaches, weight loss, arrhythmia, tremors, anxiety, addiction, and strokes. Some stimulants are allowed in competitive sports and are widely accessible, though may also be monitored by the World Anti-Doping Agency (WADA), such as caffeine. Others are banned as per the WADA (e.g., cocaine, amphetamines, ephedrine, etc.).
Sources: en.wikipedia.org
=== Monoclonal antibodies targeting the CGRP molecule === Eptinezumab (ALD403) is approved for prevention of migraine. Fremanezumab (TEV-48125) is approved for prevention of migraine. Galcanezumab (LY2951742) is approved for prevention of migraine and cluster headaches.
Mahathir received numerous awards and recognitions, including the Royal Family Order of Brunei (1997), Order of Mubarak the Great (1997), Honorary Ph.D. in Humanities from the National University of Mongolia (1997), Honorary Ph.D. in literature from Al-Azhar University (1998), U Thant Peace Award from the United Nations Organization (1999), Order of Merit of the Republic of Poland (2002), Russian Order of Friendship (2003), Honorary Ph.D. from Tsinghua University (2004), Honorary Ph.D. from the University of Santo Tomas (2012), Honorary Ph.D. in Laws from the National University of Singapore (2018), Japanese Order of the Paulownia Flowers (2018), Honorary Ph.D. from Qatar University (2019), Honorary Ph.D. from the International University of Japan (2019), Nishan-e-Pakistan (2019), and the Order of the Republic of Turkey (2019).
== Nucleotide excision repair == As illustrated above, (+)-benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide (BPDE) forms bulky covalent DNA adducts with guanines. Most of these adducts can be efficiently eliminated from DNA by the process of nucleotide excision repair. Those adducts that are not removed can cause errors during DNA replication leading to carcinogenic mutations.
Sinfield, who now favoured a softer approach, took lyrical inspiration from Homer's Odyssey, musical inspiration from jazz players like Miles Davis and Ahmad Jamal, and a trip to the Balearic Islands. Islands featured the instrumental "Sailor's Tale", with a droning Mellotron and Fripp's banjo-inspired guitar solo; the raunchy blues-rocker "Ladies of the Road", a tribute to groupies that featured Wallace and Collins singing Beatlesque backing vocals; and "Song of the Gulls", which was developed from the instrumental "Suite No. 1" from Giles, Giles & Fripp's 1968 album and would be the only time the band would utilize an orchestra. Burrell disliked Sinfield's lyrics, and one of the band members allegedly called Islands "an airy-fairy piece of shit". Released in December 1971, Islands charted at No. 30 in the UK and No. 76 in the US. That same month, the band undertook a short tour of the United States, after which Fripp informed Sinfield that he could no longer work with him and asked him to leave King Crimson. In January 1972, the remaining four members broke up acrimoniously in rehearsals, owing partially to Fripp's refusal to play a composition by Collins. He later cited this as "quality control", with the idea that King Crimson would perform the "right" kind of music. In order to fulfill touring contracts in the United States in 1972, Fripp, Collins, Burrell, and Wallace reformed with the intention of disbanding immediately after the tour. Recordings from various North American dates during January and February 1972 were released as Earthbound in June of that year.
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.